CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

被引:5
|
作者
Yi, Yonglin [1 ]
Qiu, Zhengang [2 ]
Yao, Zifu [1 ,3 ]
Lin, Anqi [1 ]
Qin, Yimin [1 ]
Sha, Ruizhan [1 ]
Wei, Ting [1 ]
Wang, Yanru [1 ]
Cheng, Quan [4 ]
Zhang, Jian [1 ]
Luo, Peng [1 ]
Shen, Weitao [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China
[3] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[4] Ctr South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
small cell lung cancer; CAMSAP1; platinum-based chemotherapy; drug sensitivity; biomarker; ACTIVATED PROTEIN-KINASE; TGF-BETA; B-CELLS; EXPRESSION; CHEMORESISTANCE; IMMUNOTHERAPY; SURVIVAL; FAMILY; MECHANISMS; MANAGEMENT;
D O I
10.3389/fcell.2021.770811
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Zou, Ting
    Liu, Jun-Yan
    She, Li
    Yin, Ji-Ye
    Li, Xi
    Li, Xiang-Ping
    Zhou, Hong-Hao
    Chen, Juan
    Liu, Zhao-Qian
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [42] Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation
    Tanaka, Ichidai
    Morise, Masahiro
    Miyazawa, Ayako
    Kodama, Yuta
    Tamiya, Yutaro
    Gen, Soei
    Matsui, Akira
    Hase, Tetsunari
    Hashimoto, Naozumi
    Sato, Mitsuo
    Hasegawa, Yoshinori
    CLINICAL LUNG CANCER, 2020, 21 (03) : 273 - +
  • [43] Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Puskas, Rita
    Bikov, Andras
    Horvath, Peter
    Lazar, Zsofia
    Kunos, Laszlo
    Nagy, Reka
    Pinter, Gabriella
    Galffy, Gabriella
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [44] ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Wang, Xiyong
    Zhu, Xiaoli
    Zhang, Hongming
    Fan, Xiaobo
    Xue, Xiulei
    Chen, Yan
    Ding, Chenbo
    Zhao, Jianwen
    Wu, Guoqiu
    JOURNAL OF CANCER, 2017, 8 (14): : 2846 - 2853
  • [45] Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy
    Ma, Kewei
    Xu, Wang
    Wang, Chang
    Li, Biao
    Su, Keju
    Li, Wei
    CANCER BIOMARKERS, 2017, 18 (03) : 297 - 303
  • [46] Patients Treated With Platinum-Doublet Chemotherapy for Advanced Non-Small-Cell Lung Cancer Have Inferior Outcomes If Previously Treated With Platinum-based Chemoradiation
    Paramanathan, Ashvin
    Solomon, Benjamin
    Collins, Marnie
    Franco, Michael
    Kofoed, Sarah
    Francis, Heather
    Ball, David
    Mileshkin, Linda
    CLINICAL LUNG CANCER, 2013, 14 (05) : 508 - 512
  • [47] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Jianli Chen
    Nashwa Emara
    Charalambos Solomides
    Hemant Parekh
    Henry Simpkins
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1103 - 1111
  • [48] Thromboembolic events (TE) in patients with meta-static non small cell lung cancer (NSCLC) treated with platinum-based chemotherapy
    Castellon-Rubio, V
    Canosa-Ruiz, L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 77 - 77
  • [49] Lymphocyte subsets predict clinical outcomes of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Liu, Y.
    Wang, J.
    Liu, L.
    Xu, X.
    Mi, X.
    Shao, M.
    Chen, D.
    Li, S.
    Xiao, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S890 - S890
  • [50] Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy
    Grossi, Francesco
    Genova, Carlo
    Rijavec, Erika
    Barletta, Giulia
    Biello, Federica
    Dal Bello, Maria Giovanna
    Meyer, Krista
    Roder, Joanna
    Roder, Heinrich
    Grigorieva, Julia
    LUNG CANCER, 2018, 117 : 64 - 69